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Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher
disease (GD), and is the first available plant cell–expressed recombinant therapeutic protein. Herein, we report
long-term safety and efficacy results of taliglucerase alfa in treatment-na€ıve adult patients with GD. Patients
were randomized to receive taliglucerase alfa 30 or 60 U/kg every other week, and 23 patients completed 36
months of treatment. Taliglucerase alfa (30 U/kg; 60 U/kg, respectively) resulted in mean decreases in spleen
volume (50.1%; 64.6%) and liver volume (25.6%; 24.4%) with mean increases in hemoglobin concentration
(16.0%; 35.8%) and platelet count (45.7%; 114.0%), and mean decreases in chitotriosidase activity (71.5%; 82.2%).
All treatment-related adverse events were mild to moderate in intensity and transient. The most common
adverse events were nasopharyngitis, arthralgia, upper respiratory tract infection, headache, pain in extremity,
and hypertension. These 36-month results of taliglucerase alfa in treatment-na€ıve adult patients with GD
demonstrate continued improvement in disease parameters with no new safety concerns. These findings
extend the taliglucerase alfa clinical safety and efficacy dataset. www.clinicaltrials.gov identifier NCT00705939.
Am. J. Hematol. 91:656–660, 2016. VC 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.
 Introduction
For more than two decades, the standard of care for patients with type 1 Gaucher disease (GD) has been enzyme replacement therapy (ERT).
The most recently approved ERT for GD is taliglucerase alfa (ELELYSOV
R
; Pfizer, New York, NY; Protalix BioTherapeutics, Carmiel, Israel). This
agent was first approved in the United States in 2012 [1], and it is the first plant cell–expressed human recombinant therapeutic protein to receive
market authorization in the United States [1,2]. Taliglucerase alfa is indicated for treatment of adults with type 1 GD in the United States, Israel,
Brazil, Australia, Canada, Chile, and other countries, and is approved for treatment of pediatric patients in the United States, Australia, Canada,
and Israel, Mexico, other countries, and for hematologic manifestations of type 3 GD in pediatric patients in Canada.
The efficacy and safety of taliglucerase alfa at two biweekly doses of 30 U/kg and 60 U/kg in treatment-na€ıve patients with GD were assessed in
a pivotal, phase III, 9-month, double-blind, parallel-group, randomized trial (NCT00376168; Study PB-06-001) [3,4]. Patients achieved significant
reductions in spleen volume, liver volume, and chitotriosidase activity along with significant increases in hemoglobin concentration following treat-
ment with taliglucerase alfa 30 U/kg and 60 U/kg. Platelet counts increased in both dose groups. All treatment-related adverse events (AEs) were
mild or moderate in intensity and no serious AEs were reported [4].
Patients who completed pivotal Study PB-06-001 were eligible to participate in extension Study PB-06-003 (NCT00705939) at the same dose as
in Study PB-06-001 [4,5]. The purpose of this report is to present the safety and efficacy results of treatment-na€ıve adult patients with GD
Additional Supporting Information may be found in the online version of this article.
1Gaucher Clinic, Shaare Zedek Medical Center, Hebrew University and Hadassah Medical School, Jerusalem, Israel; 2Pontificia Universidad Catolica de Chile, Santiago,
Chile; 3Royal Free and University College School of Medicine, Royal Free Hospital, London, United Kingdom; 4CIBERER, Hospital Universitario Miguel Servet, Zara-
goza, Spain; 5Rambam Medical Center, Haifa, Israel; 6Sapienza University of Rome, Rome, Italy; 7Mount Sinai Hospital, Toronto, Ontario, Canada; 8Clinical Center of
Serbia, Clinic of Endocrinology, Diabetes and Metabolic Disease, Belgrade University Medical School, Belgrade, Serbia; 9Servicio de Hematologia, Centro Medico Nacio-
nal Siglo XXI, Mexico City, Mexico; 10Hospital de Especialidades No1, Leon, Mexico; 11Faculty of Health Sciences, University of the Witwatersrand & Charlotte Maxeke
Johannesburg Academic Hospital, Johannesburg, South Africa; 12Protalix BioTherapeutics, Carmiel, Israel
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Conflicts of interest: AZ is a consultant for Protalix BioTherapeutics and is a member of the Speakers’ Bureau for Genzyme/Sanofi, Protalix BioTherapeutics,
and Shire; has options in Protalix BioTherapeutics; and has received honoraria from Genzyme/Sanofi, Pfizer, and Shire. In addition, the Gaucher Clinic
receives grant/research support from Genzyme/Sanofi and Shire. PG, AM, GD, HR, FG, DJA, MP, ETM, PAC, SV, and SES-M are study investigators. RC and
EB-A are employees of Protalix BioTherapeutics.
*Correspondence to: Ari Zimran, Gaucher Clinic, Shaare Zedek Medical Center, 12 Bayit Street, P.O. Box 3235, Jerusalem 91031, Israel. E-mail: azimran@
gmail.com
Contract grant sponsors: This study was sponsored by Protalix BioTherapeutics. Editorial and medical writing support was provided by Elizabeth Daro-Kaftan,
PhD, of Peloton Advantage, LLC, and was funded by Pfizer. Pfizer and Protalix entered into an agreement in November 2009 to develop and commercialize
taliglucerase alfa. Statistical analyses were performed by Target Health, who provides clinical research services to Pfizer and Protalix BioTherapeutics..
Received for publication: 25 September 2015; Revised: 17 February 2016; Accepted: 15 March 2016
Am. J. Hematol. 91:656–660, 2016.
Published online: 19 March 2016 in Wiley Online Library (wileyonlinelibrary.com).
DOI: 10.1002/ajh.24369
VC 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.
656 American Journal of Hematology, Vol. 91, No. 7, July 2016 doi:10.1002/ajh.24369
RESEARCH ARTICLE AJH
receiving taliglucerase alfa 30 U/kg or 60 U/kg for up to 36 total
months of treatment in Studies PB-06-001 and PB-06-003. Patients
who completed Study PB-06-003 were eligible to continue treatment
in an additional extension study, PB-06-007 (NCT01422187), for a
total duration of taliglucerase alfa treatment of up to 5 years [5].
 PATIENTS AND METHODS
Study design. The design of the 9-month pivotal study (PB-06-001) has been
previously reported; it was a phase III, multicenter, double-blind, randomized,
parallel-dose (30 U/kg and 60 U/kg) study of efficacy and safety in adult ERT-
na€ıve patients [4]. Study PB-06-003 was designed to be an extension study for
patients completing trials PB-06-001 and PB-06-002 (a 9-month multicenter, open-
label study of efficacy and safety in adults and children switching from imiglucerase
to taliglucerase alfa; NCT00712348). Patients from Study PB-06-001 continued
double-blind treatment for an additional 15 months in Study PB-06-003 for a total
of 24 months of double-blind treatment, at which time the investigator could
request unblinding of the patient’s dose. In the present report, data were analyzed
from patients who completed Study PB-06-001 (9 months of treatment) and con-
tinued in Study PB-06-003 (27 months of treatment) for a total duration of up to
36 months of taliglucerase alfa treatment.
The ethics committees/institutional review boards (IRBs) associated with each
study site reviewed and approved the protocol and informed consent forms. Pro-
tocol amendments were approved by the IRBs before implementation and
included extension of the potential treatment period from 15 to 30 months (24–
39 total months of taliglucerase alfa treatment) in Study PB-06-003 or until mar-
keting approval was granted by the appropriate regulatory authority, whichever
was earlier, and to remove pregnancy or nursing as an exclusion criterion and as
a reason for study discontinuation. The study was conducted in accordance with
the International Conference on Harmonisation Good Clinical Practice guidelines
and all local regulations. Written informed consent was obtained for all patients.
Patients. The main inclusion criteria for patients in Study PB-06-003 were com-
pletion of Study PB-06-001 and written informed consent to continue in Study
PB-06-003. To be eligible for Study PB-06-001, patients were required to have a
diagnosis of GD based on low glucocerebrosidase leukocyte activity level, spleno-
megaly (organ volume more than eight times the normal volume expected based
on body weight), and thrombocytopenia (platelet count< 120,000/mm3). The main
exclusion criteria from Study PB-06-003 were current use of another experimental
drug (for any disease) and presence of any medical, emotional, behavioral, or psy-
chological condition that in the judgment of the investigator would interfere with
the patient’s compliance with the requirements of the study.
Study treatment. In Study PB-06-001, patients were randomized to receive tali-
glucerase alfa 30 U/kg body weight/infusion or 60 U/kg body weight/infusion
administered intravenously at 2-week intervals. In Study PB-06-003, patients con-
tinued to receive the dose of taliglucerase alfa that they had been assigned at ran-
domization for Study PB-06-001. After 24 months, patients who had been receiving
30 U/kg could have their dose increased to 60 U/kg, if the investigator deemed it
clinically necessary.
Assessments. Efficacy evaluations included spleen volume, liver volume, hemo-
globin concentration, platelet count, and biomarkers (chitotriosidase activity and
chemokine [C-C motif] ligand 18 [CCL18] concentration). Organ volumes were
measured by magnetic resonance imaging using a single validated system and
blinded central readers, as described previously [4,6]. Safety assessments included
the incidence and severity of AEs, the incidence of serious AEs, presence of anti-
taliglucerase alfa antibodies, physical examination, clinical laboratory values, electro-
cardiogram, echocardiogram, and pulmonary function tests.
Statistical analysis. For each parameter, efficacy analyses included patients for
whom data were available at each time point through 36 months. The safety
analysis population included all patients from Study PB-06-001 who entered
Study PB-06-003 and received study drug in PB-06-003. The full analysis popu-
lation was defined as patients who enrolled in Study PB-06-003 and received at
least one dose of study drug. The completer population was defined as patients
who completed 36 months of treatment based on their study duration calculated
from the first infusion date in Study PB-06-001 and the last infusion date in
Study PB-06-003. Spleen and liver volumes were calculated as multiples of nor-
mal (MN) where normal spleen volume is 2 mL/kg and normal liver volume is
25 mL/kg [7]. For categorical variables, counts and percentages are presented.
Descriptive statistics for continuous variables, sample size (n), mean and its
standard error (SE), standard deviation, median, and range were calculated for
spleen volume, liver volume, hemoglobin concentration, platelet count, and
change in biomarker activity. The time points were counted continuously from
Study PB-06-001 through Study PB-06-003; “baseline” in this analysis denotes
baseline from Study PB-06-001 [4]. No inferential statistics were performed for
testing the change from baseline and/or for comparing between or among treat-
ment groups. Analysis of AEs was limited to events that occurred during Study
PB-06-003.
 Results
Study patients
The patient disposition is provided in Fig. S1 Supporting Informa-
tion. A total of 29 patients completed Study PB-06-001 [4]. Twenty-six
of these patients enrolled in extension Study PB-06-003, and all received
treatment; of these, 23 completed 36 months of taliglucerase alfa treat-
ment. Three patients discontinued Study PB-06-003 (all were in the
60 U/kg dose group): One patient (22-030) was unable to continue for
logistical reasons and withdrew voluntarily. Another patient (10-013)
was discontinued by the study investigator to assess possible allergic
reaction of itching and rash on the arms associated with infusions 37
and 38. One patient (12-024) stopped receiving the study drug after a
total duration of 24 months because the study protocol in that patient’s
country ended at that time point; the patient continued to receive tali-
glucerase alfa in a compassionate use program.
Baseline patient demographics and disease characteristics are shown in
Table SI Supporting Information for the 23 patients who completed
36 months of treatment. All but one patient (in the 60 U/kg group) were
Caucasian. The ratio of male to female patients was 13:10. The mean
baseline spleen volumes for both dose groups were >15 MN (range, 7.7–
54.2 MN), and the mean liver volumes for both groups were 1.5 MN.
Similar baseline patient demographics and disease characteristics were
observed in the population of 26 patients who entered the study.
Efficacy
In the full analysis population (n5 26), mean spleen volume (meas-
ured in MN), liver volume (measured in MN), platelet count, chitotriosi-
dase activity, and CCL18 concentration improved continuously through
36 months of treatment for patients receiving taliglucerase alfa 30 U/kg
and 60 U/kg. Hemoglobin concentration reached normal levels after
approximately 9 to 12 months of treatment and stayed stable through
the study duration (Figs. 1–3). Individual patient results are shown in
Tables SII–SIV Supporting Information.
Analysis of the subset of only those patients who completed 36 total
months of taliglucerase alfa treatment (n5 23) revealed the following:
In the 30 U/kg dose group, results were identical to the full analysis
population because there were no discontinuations; in the 60 U/kg
dose group, curves for the patients who completed 36 total months of
treatment (not shown) were similar to those shown in Fig. 1 through
Fig. 3 for the full analysis population. The 23 patients who completed
36 months of taliglucerase alfa treatment demonstrated substantial per-
cent changes in visceral and hematologic parameters and in biomarkers
from baseline. For the 30 U/kg and 60 U/kg dose groups, respectively,
mean (6SE) percent changes were as follows: spleen volume (measured
in MN) decreased by 50.1% (62.4%; n5 12) and 64.6% (63.3%;
n5 11), liver volume (measured in MN) decreased by 25.6% (61.5%;
n5 12) and 24.4% (64.6%; n5 11), hemoglobin concentration
increased by 16.0% (64.4%; n5 11) and 35.8% (613.2%; n5 11), pla-
telet count increased by 45.7% (612.7%; n5 12) and 114.0% (628.8%;
n5 11), chitotriosidase activity decreased by 71.5% (64.3%; n5 12)
and 82.2% (67.2%; n5 10), and CCL18 concentration decreased by
58.1% (64.8%; n5 12) and 71.0% (66.8%; n5 11).
Three patients discontinued the study prior to completion of
36 months of treatment and they, too, demonstrated improvements
in disease parameters from baseline to last observation. One patient
(12-024; 60 U/kg) discontinued after 15 months of treatment in Study
PB-06-003 (24 total months of therapy) because IRB approval for
treatment beyond the original study duration of 15 months (for a
total of 24 months) was not received in time in that patient’s country.
From baseline to 24 months, this patient showed improvements in
spleen volume (249.5%; measured in MN), liver volume (229.5%;
measured in MN), hemoglobin concentration (17.3%), platelet count
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(135.4%), chitotriosidase activity (273.0%), and CCL18 concentra-
tion (240.9%). The second patient (22-030; 60 U/kg) discontinued
because of logistical reasons; this patient experienced fatigue and
sinusitis, which were considered to be AEs that were not related to
treatment. This patient received taliglucerase alfa for a total of
24 months; from baseline to last observation, the patient showed
improvements in spleen volume (243.5%; measured in MN), hemo-
globin concentration (113.3%), platelet count (1115.2%), chitotriosi-
dase activity (270.3%), and CCL18 concentration (258.7%), while
the liver volume remained in the normal range at 0.98 MN. The third
patient (10-013; 60 U/kg) discontinued at the investigator’s request to
investigate itching and rash on the arms, which were considered pos-
sibly related to treatment after the 38th infusion. This patient also
experienced a rash under the adhesive that held the infusion catheter
in place, nervousness, general body pain, and non-related head
trauma with bleeding that occurred during a seizure (epilepsy) and
necessitated hospitalization, none of which was considered treatment
related. This patient received taliglucerase alfa for a total of 26
months; improvements were observed from baseline to last observa-
tion in spleen volume (262.9%; measured in MN), liver volume
(224.2%; measured in MN), hemoglobin concentration (113.5%),
platelet count (156.5%), chitotriosidase activity (294.4%), and
CCL18 concentration (271.8%).
Safety
Table I lists the safety findings for all 26 patients who entered
Study PB-06-003 during the extension period. The most common all-
causality AEs were arthralgia (30 U/kg, n5 4; 60 U/kg, n5 4), head-
ache (30 U/kg, n5 4; 60 U/kg, n5 3), upper respiratory tract infection
(30 U/kg, n5 3; 60 U/kg, n5 3), pain in extremity (30 U/kg, n5 2; 60
U/kg, n5 4), nasopharyngitis (30 U/kg, n5 2; 60 U/kg, n5 3), and
hypertension (30 U/kg, n5 2; 60 U/kg, n5 3). Most AEs (98.5%) were
mild to moderate in severity and transient in nature, as were all
treatment-related AEs. Ten patients experienced a total of 36 AEs con-
sidered to be related to treatment. All of these events resolved and the
patients continued the study with no change in dose. Four severe AEs,
considered unrelated to treatment, occurred in three patients during
the study: pain from a hemangioma in the left knee and surgical treat-
ment for the hemangioma resulting in a pulmonary embolism (Patient
41-022), immune thrombocytopenia (Patient 11-007), and diabetes
mellitus (Patient 40-018). There were no safety issues that evolved as a
consequence of low platelet count in the patient with the diagnosis of
immune thrombocytopenia. Three patients experienced four serious
AEs during the study: head injury in a patient with epilepsy (Patient
10-013), immune thrombocytopenia (noted above), hemangioma, and
pulmonary embolism (noted above), all of which were considered not
related to treatment and all of which resolved.
Antidrug antibodies
Thirteen patients (30 U/kg dose group, n5 5; 60 U/kg dose group,
n5 8) were found to have anti-taliglucerase alfa IgG antibodies on at
least one post-baseline visit, and two of these patients (Patient
30-008, 30 U/kg; Patient 15-016, 60 U/kg) were found to have neu-
tralizing antibodies based on an in vitro enzymatic activity assay but
were negative in a cell-based neutralizing antibody assay. Efficacy did
Figure 1. Spleen volume, expressed as multiples of normal (MN), where
normal spleen volume is 2 mL/kg times body weight (kg), and liver vol-
ume, expressed as MN, where normal liver volume is 25 mL/kg times body
weight (kg), through 36 total months of taliglucerase alfa treatment. At
each time point, values represent the mean based on all patients with
available data. Error bars represent standard error. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2. Hemoglobin concentration and platelet count through 36 total
months of taliglucerase alfa treatment. One patient did not have hemoglo-
bin concentration values at 36 months and was excluded from the analy-
sis. At each time point, values represent the mean based on all patients
with available data. Error bars represent standard error. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Zimran et al. RESEARCH ARTICLE
658 American Journal of Hematology, Vol. 91, No. 7, July 2016 doi:10.1002/ajh.24369
not appear to be impaired by development of neutralizing antibodies,
as noted in the Discussion. One of the 13 patients (Patient 30-010)
was found to have a very low anti-taliglucerase alfa IgG titer present
at baseline (before exposure). IgG titers in this patient did not
increase during treatment, and this patient was negative for anti-
taliglucerase alfa antibodies from month 12 until the end of the study.
Treatment-related AEs in patients with a positive (post-treatment) anti-
taliglucerase alfa antibody titer included a fixed drug eruption (Patient 10-
001), arthralgia (Patient 17-032), infusion-related reaction and infusion
site pain (Patient 10-005), pruritus and rash (Patient 10-013), gynecomas-
tia and pulmonary hypertension (Patient 15-016), and hypersensitivity
(Patient 30-009).
 Discussion
This multinational, multicenter, two-dose study of taliglucerase alfa
(30 U/kg and 60 U/kg) in treatment-na€ıve adult patients with GD
demonstrated improvement in visceral and hematologic disease
parameters as well as biomarkers. All treatment-related AEs were
mild or moderate in severity and resolved.
Dose increases occurred in three patients: One patient (10-001, 30
U/kg), with a baseline platelet count of 28,000/mm3, received blinded
treatment through 30 total months after which the blind was opened
and the dose increased to 60 U/kg for the remainder of the study. This
patient’s platelet counts were 28,000/mm3 at 30 months and 31,000/
mm3 at 36 months. From baseline to 36 months, the patient’s platelet
count had risen by 10.7% and the patient also showed improvements in
spleen volume (245.7%; measured in MN), liver volume (223.8%;
measured in MN), hemoglobin concentration (117.5%), chitotriosidase
activity (254.6%), and CCL18 concentration (239.7%). The second
patient (11-014) received 30 U/kg through approximately 26 months of
treatment, at which time a bone crisis occurred. This patient’s dose was
increased to 45 U/kg until the end of the study. The patient was treated
with nonsteroidal anti-inflammatory drugs, and the AE resolved after
1 month without recurrence of bone crisis throughout the remainder of
the study. From baseline through 36 months, this patient experienced
improvements in spleen volume (247.5%; measured in MN), liver vol-
ume (223.0%; measured in MN), hemoglobin concentration (17.5%),
platelet count (142.0%), chitotriosidase activity (288.3%), and CCL18
concentration (277.7%). The third patient (42-025) received blinded
treatment through 24 total months at 30 U/kg. Due to a low baseline
platelet count of 27,000/mm3 and small increase to only 33,000/mm3
(22.2%) at 24 months, the patient’s dose was increased to 60 U/kg
through the end of the study. At 36 months, the platelet count was
30,000/mm3. From baseline through 36 months, improvements were
observed in spleen volume (243.6%; measured in MN), liver volume
(217.9%; measured in MN), hemoglobin concentration (123.3%), pla-
telet count (111.1%), chitotriosidase activity (266.4%), and CCL18
concentration (251.6%).
Although the dose increase in the patient experiencing bone crisis
(11-014) had a positive impact on the resolution of the bone symp-
toms, dose escalations did not make a clinically meaningful difference
in the platelet counts of the other two patients. This poor platelet
response is presently not understood. While focal splenic lesions are
associated with refractory thrombocytopenia [8], magnetic resonance
imaging scans of both patients’ spleens did not reveal evidence of
intra-splenic lesions.
Development of neutralizing antibodies did not appear to result in
a loss of efficacy, and no changes in treatment were initiated for
either patient (15-016 and 30-008) with neutralizing antibodies; both
patients completed the study. From baseline through 36 months, two
patients (15-016 and 30-008, respectively) experienced improvements
in spleen volume (241.1 and 237.1%; measured in MN), liver vol-
ume (215.1 and 225.9%; measured in MN), chitotriosidase acti-
vity (280.9 and 260.5%), and CCL18 concentration (263.7 and
227.2%). Hemoglobin concentration decreased nominally by 0.8%
from 13.2 g/dL at baseline in Patient 15-016 but remained in the nor-
mal range and increased by 10.3% in Patient 30-008, who was anemic
at baseline. Platelets increased by 71.8% in Patient 15-016 and
showed a clinically insignificant decrease from baseline in Patient
30-008 (21.2% from 86,000/mm3 at baseline). The numbers of
patients reported as developing anti-taliglucerase alfa IgG antibodies
in Study PB-06-003 are higher than those seen in previous, shorter-
term studies [1,4], and are likely due to increased sensitivity as part
Figure 3. Mean percent change in chitotriosidase activity and CCL18 con-
centration mean percent change from baseline through 36 total months of
taliglucerase alfa treatment. One patient in the 60 U/kg dose group (30–111)
was found to have no chitotriosidase activity at baseline; therefore, no chi-
totriosidase activity data were available during the study, and the patient
was excluded from chitotriosidase analysis but was followed via CCL18. At
each time point, values represent the mean based on all patients with avail-
able data. Error bars represent standard error. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
TABLE I. AEs Occurring During the Extension Period (Safety
Population; n5 26)
No. of AEs
(No. of patients)
% of
total AEs
Total AEs 275 (24) 100
Mild or moderate 271 (23) 98.5
Severe or very severe 4 (3) 1.1
30 U/kg 2 (1)
60 U/kg 2 (2)
Non–treatment-relateda 239 (24) 86.9
Treatment-relatedb 36 (10) 13.1
a Probably or definitely not related to treatment.
b Possibly, probably, or definitely related to study treatment.
AEs: adverse events.
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of assay modifications resulting in different antibody sample positivity
reporting. These modifications were instituted to establish statistically
based cut point definitions consistent with current industry practices.
In conclusion, these long-term results of taliglucerase alfa demon-
strated continued improvement in the clinical parameters with no
new safety concerns through 36 months of treatment in treatment-
na€ıve adult patients with GD. These results extend the clinical safety
and efficacy profile of taliglucerase alfa in patients with GD.
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